Company profile: Lexicon Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of precise medicines for human disease, including INPEFA (sotagliflozin), a once-daily oral tablet that reduces the risk of cardiovascular death, heart failure hospitalization and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. Pipeline includes LX9211 for DPNP (AAK1) and sotagliflozin for type 1 diabetes (US regulatory) and HCM (preclinical).
Products and services
- INPEFA (sotagliflozin): Once-daily oral tablet lowering cardiovascular death, heart failure hospitalization, and urgent heart failure visits in adults with heart failure or type 2 diabetes and other cardiovascular risk factors
- Sotagliflozin for Type 1 Diabetes: Dual SGLT2/SGLT1-targeting drug candidate engineered to treat Type 1 Diabetes, with ongoing regulatory engagement in the US
- LX9211: AAK1-targeting drug candidate in development for the treatment of Diabetic Peripheral Neuropathic Pain (DPNP), with pharmacologic activity directed at AAK1 to treat diabetic neuropathic pain
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lexicon Pharmaceuticals
QuanDx
HQ: United States
Website
- Description: Provider of life science reagents and molecular diagnostic kits, including the Q-Fusion multiplex system and Q30 screening kit for leukemia fusion genes, Yin-Yang Probes for affordable, multiplexed tests for various diseases, and a High Risk HPV Genotyping Assay detecting 14 types of high-risk HPV with automatic result interpretation in a single tube reaction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full QuanDx company profile →
SeQure Dx
HQ: United States
Website
- Description: Provider of safety data and diagnostic platforms for on- and off-target CRISPR gene editing therapies. Offers NoteSeQ (ONE-seq) for profiling off-target sites, ScopeSeQ for validating candidate edits via next-generation sequencing, risk assessment across the development lifecycle, discovery/IND support, clinical trial patient risk management, and post-approval diagnostic management with patient and physician education.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SeQure Dx company profile →
NorthGene
HQ: United Kingdom
Website
- Description: Provider of medical testing, health care and other services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NorthGene company profile →
WestBred
HQ: United States
Website
- Description: Provider of highest yield potential wheat seed designed for regional conditions, including certified single-variety seed containing no other crops, foreign material, or certain seed-borne diseases; Clearfield Plus production system for grass and broadleaf weed control using Beyond herbicide; grower resources such as optimal seeding rate guidance; intellectual property protection for varieties; and the National Wheat Yield Contest.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full WestBred company profile →
MIDI
HQ: United States
Website
- Description: Provider of chemical analysis and microbial identification solutions for agriculture and environmental microbiology laboratories.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MIDI company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lexicon Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lexicon Pharmaceuticals
2.2 - Growth funds investing in similar companies to Lexicon Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lexicon Pharmaceuticals
4.2 - Public trading comparable groups for Lexicon Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →